Skip to main content
. 2023 Sep 13;7:90. doi: 10.1038/s41698-023-00438-0

Table 2.

Analysis of pathological and histological markers.

Univariate in the combined, AI, and FUL cohorts
Comparison (v1 vs v2) N1 N2 HR p value N1 N2 HR p value N1 N2 HR p value
HER2 0+ vs HER2 1+ 43 91 1.2392 0.445 39 66 0.889 0.704 4 25 3.860 0.188
HER2 0+ vs HER2 2+ 43 107 1.1357 0.645 39 82 0.8857 0.682 4 25 3.532 0.221
PR− vs PR+ 104 144 0.5859 0.00246 73 121 0.5736 0.00814 31 23 0.7865 0.477
Non-visceral vs visceral metastasis 146 132 1.4196 0.0331 117 92 1.3240 0.164 29 40 1.3728 0.281
Distant Mets vs local disease 234 14 0.4116 0.0801 198 11 0.4751 0.204 66 3 0.3024 0.239
No prior endocrine vs prior endocrine therapy 97 181 1.9834 0.00041 91 118 1.7144 0.0123 6 63 2.2928 0.165
SBR1 vs SBR2 28 152 1.3715 0.2907 20 110 1.2392 0.5736 8 42 1.7402 0.254
SBR1 vs SBR3 28 69 2.0574 0.0227 20 56 2.3817 0.0272 8 13 1.5936 0.407
 Tubular differentiation 1 vs 2 10 40 1.1825 0.716 5 32 2.3227 0.260 5 8 0.7368 0.649
 Tubular differentiation 1 vs 3 10 202 1.4305 0.394 5 151 2.4321 0.216 5 51 1.2789 0.642
 Nuclear pleomorphism 1 vs 2 15 149 1.203 0.602 9 114 1.0953 0.847 6 35 1.9587 0.218
 Nuclear pleomorphism 1 vs 3 15 89 1.704 0.138 9 66 1.8368 0.200 6 23 1.7881 0.302
 Mitotic rate 1 vs 2 134 69 1.2001 0.353 97 53 1.3929 0.17457 37 16 0.9408 0.857
 Mitotic rate 1 vs 3 134 42 1.5627 0.0535 97 34 2.3281 0.00154 37 8 0.5587 0.277
Comparison (v1 vs v2) N1 N2 HR Covariate p value Model p value
Multivariate in the combined cohort
 PR− vs PR+ 104 144 0.6019 0.0062 4e−5
 Non-visceral vs visceral metastasis 146 132 1.2441 0.24502
 No prior endocrine vs prior endocrine therapy 97 181 1.6544 0.0209
 SBR1 vs SBR2 28 152 1.6633 0.13532
 SBR1 vs SBR3 28 69 2.7842 0.00404
Multivariate in the AI cohort
 PR− vs PR+ 73 121 0.5739 0.0116 3e−4
 Non-visceral vs visceral metastasis 117 92 1.2368 0.3490
 No prior endocrine vs prior endocrine therapy 91 118 1.3940 0.1602
 SBR1 vs SBR2 20 110 1.3018 0.5179
 SBR1 vs SBR3 20 56 2.6599 0.0202
Multivariate in the FUL cohort
 PR− vs PR+ 31 23 0.8479 0.6587 0.4
 Non-visceral vs visceral metastasis 29 40 0.8806 0.7306
 No prior endocrine vs prior endocrine therapy 6 63 2.9086 0.1751
 SBR1 vs SBR2 8 42 3.1049 0.0769
 SBR1 vs SBR3 8 13 3.3841 0.0848

Univariate and multivariate analysis of common markers measured in ER+/HER2− breast cancer within the combined, AI, and fulvestrant cohorts of patients.